HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Successful cancer treatment may lead to cardiac complications later
-
- Concurrent palliative care reduced symptom burden in prostate cancer
- Expert panel discusses potential link between angiotensin receptor blockers, cancer
- High-dose radiation techniques produced differing toxicity profiles
- Panel proposes consensus definition of cisplatin ineligibility criteria
- PSA velocity may not contribute to prostate cancer screening process
- Variability observed in muscle-invasive bladder cancer treatment
- The complexities of honest communication William Wood, MD
- Allo-HCT in first complete remission extended life expectancy for some intermediate- and unfavorable-risk AML
-
- Aspirin, warfarin may reduce thromboembolic events in multiple myeloma
- BMI, physical activity may be linked to breast cancer risk
- Chemoimmunotherapy extended OS, PFS in patients with CLL
- Clinician involvement in cancer clinical trials may be insufficient
- Everolimus may be viable option for advanced pancreatic neuroendocrine tumors
- Full genomic sequencing of prostate cancer tumors may lead to better therapeutic interventions
- HER-2 status may change in breast cancer metastases
- Rivaroxaban may offer safe, effective treatment of venous thrombosis
-
- Screen detection associated with reduction in 10-year breast cancer-specific mortality
- Significance of JAK2 burden in polycythemia vera treatment remains uncertain
- Trastuzumab showed clinical benefit in HER-2–positive breast cancer
- Women should avoid pregnancy for up to 12 months after rituximab therapy
- Cervical cancer prevention program prevented cancer death in women with HIV
- Inappropriate use of medical imaging may be more widespread than previously thought
- miR-378 may be linked to treatment response in ovarian cancer
- PCPs less likely to refer patients to gynecologic oncologists
-
- Radiation between chemotherapy cycles efficacious in uterine papillary serous carcinoma
- Eribulin: another new chemotherapy for breast cancer Laura Boehnke Michaud, PharmD; Karen Eckmann, PharmD, BCOP